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2747more formal development of a possible target trough concentration
range.
An example of a range for this individual may be derived by
adjusting the lines of best ﬁt of the event risk–concentration curves
by using event weighting according to the hazard ratios of death
described by Eikelboom et al. (8) and then combining the lines of
best ﬁt (Fig. 1). Note that for the patient described here, the
therapeutic range is relatively narrow compared with the 10th to
90th percentiles of trough concentrations and would certainly not
be considered a wide therapeutic range.
4. Trough concentrations outside the 10th and 90th percentiles.
By deﬁnition, 20% of individuals treated with dabigatran etex-
ilate in the RE-LY study had concentrations outside the 10th to
90th percentiles of trough plasma dabigatran concentrations. Did
the outcomes for these individuals differ from the rest of the
cohort? Dose adjustment to “improve” the drug exposure for these
20% of patients may be beneﬁcial. Could the authors describe the
characteristics of the individuals with trough plasma dabigatran
concentrations that were below the 10th percentile and above the
90th percentile?*Paul K. L. Chin, MB ChB
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Between High-Density
Lipoprotein Cholesterol
and Inﬂammatory Response
in Cardiovascular DiseaseIn the recently published post-hoc analysis from the COURAGE
(Clinical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation) trial, low high-density lipoprotein cholesterol
(HDL-C) levels remained a powerful and independent predictor
of cardiovascular (CV) risk in 2,193 patients with stable ischemic
heart disease (1). This ﬁnding was also conﬁrmed in patients with
low-density lipoprotein cholesterol (LDL-C) levels <70 mg/dl.
However, both in primary prevention, as in the JUPITER
(Justiﬁcation for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) trial (2), as in sec-
ondary prevention (3), potent statin therapy may lead to no
relation between HDL-C and residual CV risk. Furthermore, the
AIM-HIGH (Atherothrombosis Intervention in Metabolic
Syndrome With Low HDL/High Triglycerides: Impact on
Global Health Outcomes) Investigators have shown that there
was no incremental clinical beneﬁt from the addition of niacin to
statin therapy despite a signiﬁcant and sustained increase in
HDL-C (4).
We feel that the missing link to understanding this unclear
relation of HDL-C and residual CV risk in patients using intensive
lipid-lowering medication relies on the degree of systemic inﬂam-
mation. In fact, although HDL-C modulates cholesterol avail-
ability in the cell membrane, which promotes reverse cholesterol
transport (HDL-C’s main antiatherogenic effect), it also inﬂuences
the immune response, the hematopoietic stem cells maturation,
and ultimately the leukocyte number (5–7). HDL-C also plays a
key role in the humoral innate immune response, as HDL-C in-
duces the long pentraxin 3 (PTX3), and PTX3 levels are increased
in animal models with genetically increased HDL levels. PTX3
deﬁciency then results in increased inﬂammation and bone marrow
monocytosis (8). Again, in a prospective multiethnic trial that
enrolled patients with ST-segment elevation myocardial infarction
(9), high levels of systemic inﬂammation, deﬁned by increased
levels of interleukin-6 and C-reactive protein (CRP) within 6 h of
the onset of symptoms, were associated with a signiﬁcant reduction
in HDL-C compared with patients with ST-segment elevation
myocardial infarction and low levels of systemic inﬂammatory
markers (10). Furthermore, inﬂammation induces major changes in
HDL-C composition. Mediators of inﬂammation such as tumor
necrosis factor–alpha and interleukin-6 induce expression of serum
amyloid A and group IIA secretory phospholipase A2, which
dramatically alter HDL apolipoprotein content and levels, respec-
tively (7). All this evidence suggests a profound link between in-
ﬂammatory response in patients with atherosclerosis and the
levels and composition of HDL-C. In our opinion, this link is
underexplored in the subanalyses of large clinical trials aimed at
increasing HDL-C levels and in studies on the predictive value of
HDL-C levels on residual CV risk.
Correspondence JACC Vol. 63, No. 24, 2014
June 24, 2014:2745–9
2748Have the authors investigated in their post-hoc analysis (1)
whether HDL-C levels were associated with alterations in whole
blood count or other established immune-inﬂammatory markers,
such as CRP? Can the whole blood count or CRP levels limit the
power of prediction of HDL-C when adjusted for inﬂammatory
markers?
As a further speculation, the limited clinical beneﬁt of niacin or
cholesteryl ester transfer protein inhibitors, despite effective in-
creases in HDL-C levels (4,11), could be associated with an
inconsistent enhancing effect on immune-inﬂammatory response
or with the modulation of HDL subclasses unable to tune immune
response during atherogenesis.*Enrico Ammirati, MD
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367:2089–99.Mechanisms Explaining
the Relationship Between
Metabolically Healthy Obesity
and Cardiovascular RiskRecently, much interest has been given to the novel concept of
metabolically healthy obesity (MHO). It could help to direct the
limited resources that are available for prevention of metabolic
diseases to the people at highest risk (1). Mørkedal et al. (2) now
showed that individuals with MHO are not at increased risk of
acute myocardial infarction (AMI) compared with normal-weight,
metabolically healthy subjects. In contrast, they have an increased
incidence of heart failure (HF) (2). Lavie et al. (3) convincingly
discussed mechanisms, explaining why obesity itself, and not
necessarily only metabolic abnormalities such as hypertension,
dyslipidemia, hyperglycemia, and subclinical inﬂammation, has an
impact on the development of HF. Most recently, a meta-analysis
questioned the concept of MHO for its relevance for cardiovascular
events (4). The study of Mørkedal et al. now can show that it is
necessary to separate the predictive effects of MHO on AMI and
HF when it comes to the prediction of cardiovascular disease.
The study by Mørkedal et al. (2) cannot provide mechanisms
explaining the lower risk of AMI in those with MHO compared
with subjects with metabolically unhealthy obesity. We could show
that MHO is associated with a moderately reduced visceral fat
mass, but, more importantly, with a largely reduced liver fat content
(5). We also provided evidence that genetic variability in the adi-
ponectin receptor 1 gene determines the prevalence of MHO and
that MHO correlates with lower levels of the liver-secreted
glycoprotein fetuin-A (5). Particularly lower production of this
proinﬂammatory hepatokine, which affects glucose and lipid
metabolism and induces subclinical inﬂammation (6,7), may
explain the lower risk of AMI in MHO.
Regarding preventive strategies in MHO, Mørkedal et al. (2)
refer to a small study indicating that lifestyle intervention may
decrease insulin sensitivity and thus be harmful for people with this
condition (8). However, we could show in a larger study that
visceral fat mass decreased and insulin sensitivity remained high
during a lifestyle intervention in subjects with MHO (9).
The concept of MHO has gained much interest in the scientiﬁc
community. However, because of its complex nature and the not
fully understood mechanisms involved in the causes and conse-
quences of MHO, it is very important to carefully deal with this
popular concept when it comes to the prediction and prevention of
metabolic diseases.*Norbert Stefan, MD
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